Canada: The Supreme Court Refuses To Grant Leave To Hear "Promise Of The Patent" Appeals

Last Updated: April 30 2015
Article by Adam Bobker and Teresa MacLean

On April 23, 2015, the Supreme Court of Canada denied leave to hear an appeal from the Federal Court of Appeal decision in Apotex Inc v Pfizer Canada Inc, et al and Mylan Pharmaceuticals ULC v Pfizer Canada Inc, et al, 2014 FCA 250 (the Court of Appeal decision). As there has been much discussion in the area of law surrounding utility and the "promise of the patent", guidance from the Supreme Court of Canada would have been welcome. However, the decision reached by the Federal Court of Appeal in this case takes a balanced approach to determining whether a patent contains an invalidating unfulfilled promise.

The leave applications relate to Canadian Patent No. 2,177,576 (the '576 Patent), which expired on November 14, 2014. The '576 Patent was directed to a new class of non-steroidal anti-inflammatory drugs (NSAIDs) and claimed new compounds including celecoxib, sold by Pfizer under the name Celebrex, and their associated uses. Pfizer sought orders prohibiting the Minister of Health from issuing a Notice of Compliance to Apotex and to Mylan in respect of their generic versions of the drug Celebrex. The Federal Court allowed both of Pfizer's applications and issued prohibition orders against Mylan (2014 FC 38) and Apotex (2014 FC 314). Apotex and Mylan appealed the orders. The appeals were consolidated and refused by the Federal Court of Appeal.

Apotex advanced four distinct arguments before the Court of Appeal: i) lack of utility in treating inflammation in humans, ii) lack of utility in reducing side effects, iii) lack of utility in preventing colorectal cancer, and iv) insufficient disclosure. Mylan's submissions focused on an argument of lack of utility in reducing side effects. The parties also alleged that the Federal Court breached the principles of comity and stare decisis in failing to follow the construction of the '576 Patent reached by Justice Hughes in GD Searle & Co v Novopharm Ltd (2007 FC 81) and affirmed by the FCA (2007 FCA 173). Further, the parties argued that it was abuse of process for the Federal Court judge to accept Pfizer's pleading that reduced harmful side effects were not promised as it had conceded that point in the Novopharm decision.

Justice Noël began his analysis by stating that the minimum statutory requirements for utility are quite low - no more than a "scintilla" - and the promise doctrine is an exception to this standard. An inventor need not describe any particular utility and will be held to a higher utility standard only where a "clear and unambiguous" promise has been made. Further, when allegations of unfulfilled promises regarding a patent are made, the patent will be construed in the patentee's favour where it can reasonably be read by a skilled person to exclude any such promises.

Apotex argued that where a patent "lays claim" to a particular use, that use must form part of the promise. Justice Noël rejected this broad proposition, stating "when a result or advantage is asserted in a patent's claims, it will generally be seen as a promise of utility." Apotex had failed to establish that any of the '576 Patent's claims describe use in humans as an advantage of the claimed compounds and the '576 Patent made no explicit promise of treatment in humans. Justice Noël also rejected the parties assertions that the '576 Patent promised utility in reducing side effects.

Apotex further argued that any given promise must be construed as overarching and, since the promise of preventing colorectal cancer was neither demonstrated nor soundly predicted as of the filing date, the patent as a whole should be invalidated. The Court of Appeal held that there was no support in the jurisprudence for this proposition. At most, the cases cited by Apotex demonstrate that a promise may be construed to extend to each of the patent's claims and there was no general statement of law made on the matter.

Regarding sufficiency of disclosure, Apotex's asserted that Pfizer concealed its "true invention" among a group of compounds that it knew were not useful, resulting in insufficient disclosure. This was rejected since Apotex had not advanced these arguments in its Notice of Allegation.

Additionally, the appellants had argued at the Federal Court that Pfizer was abusing the process of the court as it had conceded in the Novopharm NOC proceeding that reduced side effects were necessary to the utility of the '576 Patent. Apotex asserted that a party cannot elevate an inventive concept to support non-obviousness and read then it down in the utility analysis, that a party cannot take inconsistent positions in different proceedings, and that a party cannot re-litigate an issue previously decided with the aid of additional evidence it chose not to adduce in the earlier proceeding. The Court of Appeal dismissed these arguments, stating that there may be instances where a concession made in one proceeding may be binding in another, but there is no existing precedent on point and Federal Court judge had not committed any error in exercising his discretion to hold otherwise.

Apotex and Mylan further asserted that under the doctrine of stare decisis, the Federal Court was bound by the construction of the '576 Patent reached by Justice Hughes and upheld by the Court of Appeal in the Novopharm decision. There, it was held that a promise of reduced side effects had been made. Justice Noël emphasized that the doctrine of stare decisis obliges courts to render decisions that are consistent with previous decisions made by higher courts. However, not every statement in a given judgment is binding on lower courts. An appellate judgment will be authoritative for its ratio decidendi, the reasoning necessary to reach a decision on the issues litigated. Statements of obiter dicta will vary in authoritative force from helpful commentary to guidance. The Novopharm Court of Appeal decision did not decide that reduced side effects were necessary to the utility of the '576 Patent, rather, it decided two narrow issues relating to the correct claim date and a point of obviousness. Thus, there is no authoritative decision relating to utility of reducing side effects reached by a higher court that would have bound the Federal Court in subsequent litigation.

Regarding the doctrine of comity or horizontal stare decisis, Justice Noël reiterated that decisions reached by judges of the same court are not binding on each other. There may be uncertainty created when two judges reach distinct results on the same question of law. However, there is no legal sanction for a judge's failure to abide by comity.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Adam Bobker
Teresa MacLean
Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions